Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLIMACTERIC”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,189 records · Page 66Linked to original sources
PubMed1990

[Bone mineral density in climacteric. Identification of patients with risk of developing osteoporosis].

The bone mineral density (BMD) of the lumbar spine was determined by dual photon absorptiometry in 98 normal females: 26 premenopausal between 40 and 48 years of age and 72 unselected women 1 to 20 years after the onset of menopause, all of them attending the Menopause Clinic of the Hospital. The results were as follows: Premenopause 1.20 +/- 0.09; Postmenopause: 1.8 years: 1.16 +/- 0.10; 5.3 years: 1.10 +/- 0.12; 9.0 years: 1.06 +/- 0.12; 15.1 years: 1.01 +/- 0.11 g/cm2. The total bone loss during the period of observation was 16%. The cross-sectional data appears to fit an exponential curve with approximate diminution of 2.0%/year at the onset and 1%/year 10 years after the menopause. The individual values obtained in 45 females between 1 and 10 years postmenopause are plotted in Figure 2. Two patients with BMD below 0.9 g/cm2 were specially studied. One of them had asymptomatic primary hyperparathyroidism and the other overt osteoporosis with a crush fracture of a dorsal vertebra. Following the average bone loss of the group and assuming that the BMD should not fall at age 65 below the theoretical threshold for spine fractures (0.98 g/cm2) a risk curve was designed: 58% of the women were above and 42% below. This percentage is similar to the number of females who suffer osteoporotic fractures at age 70. Considering the Quetelet index (weight in kg/height in m2) the females were divided in 3 groups: above 30, between 30 and 23 and below 23.(ABSTRACT TRUNCATED AT 250 WORDS)

Absorptiometry, Photon↗
PubMed1990

[Transcutaneous estradiol treatment in the climacteric].

The effect transcutaneous oestradiol for four months supplemented by medroxyprogesterone (Perlutex) from the 12th to 26th day of every month was assessed in an open uncontrolled prospective investigation in 34 women with menopausal symptoms and follicle stimulating hormone greater than 40 international units and luteinizing hormone greater than 25 international units. A marked effect was found on sweating and hot flushes and other menopausal complaints as expressed by Kupperman's menopausal index. Serum oestradiol increased during the first two months to follicular phase values and this was followed by an unexplained decrease after the fourth month which did not, however, result in aggravation of the symptoms. No alterations were found in steroid-hormone-binding globulin, lipids and body weight. Whether the patients placed the plasters in the hip or abdominal regions was found to be of no significance. Seventeen patients had no side effects of the treatment. Nine patients had transient skin symptoms which disappeared spontaneously. Five patients had mastalgia which disappeared after reduction of the Perlutex dose. One patient developed metrorrhagia. A total of three patients abandoned the treatment: one on account of skin symptoms, one on account of high blood pressure and a third on account of psychiatric symptoms which were unrelated to the treatment. A total of 28 patients wanted to continue treatment after the fourth month.

Administration, Cutaneous↗
PubMedDate not supplied

Clinical experience with transdermal estradiol in the treatment of the climacteric.

Results of clinical studies have revealed that the transdermal therapeutic system of estrogen administration (Estraderm, Ciba Pharmaceutical Co., Summit, New Jersey) is both effective and well tolerated. Relief of hot flushes and vaginal atrophy has been shown to equal oral administration of conjugated equine estrogens and early experience suggests that the bone sparing effect is maintained. The patch has no effect on certain liver proteins; safety variables have shown no adverse biochemical changes. Moderate bleeding has occurred in some patients with an intact uterus but can be controlled by the addition of a progestogen. The incidence of endometrial hyperplasia and breast tenderness has been relatively low, and minor side effects (such as fluid retention) have been limited. Several investigators have evaluated skin irritation resulting from the systems. Some erythema has been reported but serious ulcerations or sloughing did not occur. A survey of patient attitudes comparing oral administration and transdermal systems indicated a preference for the transdermal method.

Administration, Cutaneous↗